US Medicare Rx drug cover could cost $1,000 billion over 10 years, says CBO

23 March 2001

The US Congressional Budget Office has estimated that, given theincreasing costs of medication, Medicare beneficiaries will consume prescription drugs worth a total of $1,500 billion during 2002-2011, according to the Office's director, Dan Crippen.

Therefore, said Mr Crippen in testimony before the Senate Finance Committee, President George W Bush's proposed spending of up to $153 billion on a Medicare prescription drug plan over the next 10 years would create a benefit that would have to be "pretty targeted" or, for a universal benefit it would be "pretty thin," and would "not provide a great deal for any one person," he said, according to a Reuters report.

Mr Crippen told the Committee hearing that a prescription drug benefit which covered 50% of enrollees' annual spending would cost approximately $728 billion to 2011, while covering all beneficiaries' costs of more than $1,000 per year would raise this total to around $1,100 billion, which is seven times more than Pres Bush has budgeted for such a provision in the period. If the benefit were to cover costs above $5,000 annually, he estimated that the Medicare bill to 2011 would total about $365 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight